AACR: Novel Personalized Vaccine Feasible for Head and Neck Cancer
TUESDAY, April 9, 2024 -- The novel viral-based personalized cancer vaccine, TG4050, which encodes up to 30 patient- and tumor-specific sequences is feasible and safe for patients with resected head and neck squamous cell carcinoma, according to a...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Head and Neck Cancer | HNSCC | Pharmaceuticals | Skin Cancer | Squamous Cell Carcinoma | Vaccines